1. Value in Health Regional Issues
Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions 
Hong Li, PhD, MPH, Gordon G. Liu, PhD, Jing Wu, PhD, Jiu-Hong Wu, PhD, PharmD, Chao-Hui Dong, PhD, Shan-Lian Hu, MD, MSc 
Value in Health Regional Issues 
Volume 15, Pages (May 2018)
DOI: /j.vhri
Copyright © Terms and Conditions

2. Fig. 1
The China National Formulary (CNF). The A List contains medications that all provinces must adopt 100%, including 520 medicines on the Essential Medicine List; however, provinces can modify medications in the B List up to 15% based on local situations. CFDA, China Food and Drug Administration.
Value in Health Regional Issues  , DOI: ( /j.vhri )
Copyright © Terms and Conditions